help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on February 5, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1296
A more recent version of this article appeared on April 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/4/1386    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Makras, P.
Right arrow Articles by Papapoulos, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Makras, P.
Right arrow Articles by Papapoulos, S. E.
Related Collections
Right arrow Pediatric Endocrinology
Right arrow Calcium and Bone Metabolism

Submitted on June 11, 2007
Accepted on January 29, 2008

Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene

Polyzois Makras, Neveen A.T. Hamdy, Sarina G. Kant, and Socrates E. Papapoulos*

Department of Endocrinology and Metabolic Diseases, Department of Clinical Genetics, Leiden University Medical Center, The Netherlands

* To whom correspondence should be addressed. E-mail: m.v.Iken{at}lumc.nl.

Context: X-linked Hypophosphatemic Rickets (XLH) is characterized by hypophosphataemia and growth retardation. Early diagnosis and treatment improve growth.

Objective: To describe long-term observations of a family with XLH due to a novel mutation of the PHEX gene with unusual clinical features, including normal growth.

Patients: The mother and her two sons were followed in the same institution for nearly 30 years.

Results: The mother had hypophosphatemia and normal height (Z score: -0.6) without ever receiving any treatment. Her two sons achieved final heights of 183.7 cm (Z score: -0.01) and 182.7 cm (Z score:-0.18), respectively, despite late initiation of treatment with phosphate and low serum phosphate levels. In addition, they had reversible proximal myopathy which took about 7 years to resolve in one of them. Direct sequencing of the PHEX gene revealed a new splice site mutation in intron 4 of the gene (IVS4+6T>C) resulting in skipping of exon 4.

Conclusions: Three members of a family with XLH due to a novel mutation of the PHEX gene had a normal growth pattern despite late diagnosis and treatment of the two boys and no treatment at all of their mother. The pathophysiological basis of this phenotype-genotype association warrants further investigation.


Key words: X-linked Hypophosphatemic rickets • growth • myopathy • height • treatment







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society